
Nektar Therapeutics NKTR
$ 83.81
0.0%
Annual report 2023
added 03-05-2024
Nektar Therapeutics Total Current Liabilities 2011-2026 | NKTR
Annual Total Current Liabilities Nektar Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51.3 M | 68.2 M | 85.2 M | 116 M | 354 M | 82 M | 56.2 M | 72.2 M | 61.2 M | 64 M | 98.2 M | 78.5 M | 276 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 354 M | 51.3 M | 112 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
4.59 M | $ 0.88 | - | $ 6.47 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
395 M | $ 22.67 | - | $ 3.76 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Galectin Therapeutics
GALT
|
8.03 M | $ 2.32 | - | $ 148 M | ||
|
Greenwich LifeSciences
GLSI
|
1.56 M | $ 22.8 | - | $ 297 M | ||
|
Avenue Therapeutics
ATXI
|
1.1 M | - | -52.27 % | $ 4.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
36.9 M | - | 17.91 % | $ 11.1 M | ||
|
Atreca
BCEL
|
16.3 M | - | -11.76 % | $ 5.79 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | ||
|
Innoviva
INVA
|
49.7 M | $ 23.69 | - | $ 1.6 B | ||
|
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.09 | - | $ 437 M | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 23.29 | - | $ 2.96 B | ||
|
Jaguar Health
JAGX
|
40.7 M | $ 0.24 | - | $ 560 K | ||
|
KalVista Pharmaceuticals
KALV
|
57.4 M | $ 19.24 | - | $ 1.04 B | ||
|
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.48 | - | $ 394 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 2.91 | - | $ 4.79 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B |